CSF ACR 2023 PsA Highlights

ACR 2023 

Congress Preview 

Psoriatic Arthritis 

Faculty Introduction 

Dear Colleagues, 

Welcome to this year’s selection of ACR abstracts on PsA and my ‘Highlights’. We have selected 26 abstracts that cover 

a range of key topics in the management of psoriatic arthritis that I believe will be of particular interest to you. 

Sunday’s poster session features comprehensive data from phase 2 and phase 3 trials of bimekizumab (0511 and 0527) 

and deucravacitinib (0485, 0508, and 0509). These studies, authored by Elaine Husni, Lihi Eder, and Philip Mease, provide 

insights into the efficacy, safety, and tolerability of these treatments. As part of an abstract session, Alan Kivitz (0776) will 

also discuss the efficacy and safety of secukinumab as a treatment for PsA. 

Launching into Monday, you’ll be met with another poster session with a focus on the treatment of spondylarthritis, 

including psoriatic arthritis, with posters from a variety of esteemed authors. Here you’ll find 16 of our recommended 

posters, with data from studies such as the phase 3 COSMOS study (1428) and the KEEPsAKE 1 and 2 trials (1434 

and 1435). Later that day the poster Prediction of Low Disease Activity in Patients with Ankylosing Spondylitis Treated 

with Secukinumab in Real World – Data from a German Observational Study by Uta Kiltz (1390) will also be presented. 

In addition, two abstracts by Philip Mease on the efficacy of Izokibep and the results from the FOREMOST study will be 

presented (1688 and 1691) that we recommend looking out for. 

On Tuesday, three more posters of note will be presented; Bimekizumab Treatment in Patients with Active PsA and Prior 

Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and Its Open-Label 

Extension up to 1 Year by Laura Coates (2230), Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis 

and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration by Marion Pons (2199) 

and Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized 

Phase 3 Study by Peter Taylor (2251). 

On the Wednesday, we conclude the congress with a scientific session, a final poster presentation, and late-breaking 

abstracts. These sessions promise exciting updates on PsA therapy. You can find more details in this brochure. 

As always, thank you for your continued support. We hope you have a fantastic time and thank you for being a part 

of ACR 2023! 

Kind regards 

Professor Laura Coates 

PS. Make sure you get all the insights from this ACR by downloading our other highlights brochures, and if you want to 

see the top picks for Lupus head on over to www.lupus-forum.com where you’ll find the top ACR picks and their top 

abstracts in the field of lupus therapeutics. 

Register for FREE content at 

www.cytokinesignalling.com 

Follow us at: 

Cytokine Signalling Forum 

SPONSORSHIP AND UNRESTRICTED 

EDUCATIONAL GRANTS FROM 

DEVELOPED UNDER 

THE AUSPICES OF THE

KEY: 

H 

Highlights 

ABSTRACT SESSION 

POSTER SESSION 

SCIENTIFIC SESSION 

Key Presentations 

Sunday, 12 November 2023 

09:00– 

11:00 

0338 

09:00– 

11:00 

0452 

09:00– 

11:00 

0485 

0498 

0499 

0508 

0509 

PATIENT OUTCOMES, PREFERENCES, & 

ATTITUDES POSTER I 

Comparative Disease Burden in Patients with Rheumatoid 

Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis: Data 

from COVAD Patient-reported E-survey 

Diego Benavent 

RA – TREATMENTS POSTER I 

Real Life Safety and Survival of Targeted Therapies in 

Arthritis Patients over Age of 65 

Elena Grau Garcia 

SPONDYLOARTHRITIS INCLUDING PSORIATIC 

ARTHRITIS – DIAGNOSIS, MANIFESTATIONS, 

& OUTCOMES POSTER I: PSA 

Sex and Treatment-associated Outcomes in Patients 

with Active Psoriatic Arthritis Treated with Deucravacitinib, 

an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, 

in a Phase 2 Trial 

Lihi Eder 

Biological Therapies for Psoriasis and Psoriatic Arthritiseffects 

on Future Risk Development of Major Adverse 

Cardiovascular Events (MACE) 

Howard Amital 

Durability of Response Among Patients with Psoriatic 

Arthritis (PsA) Using Biological or Targeted Synthetic 

Disease-Modifying Antirheumatic Drugs in the CorEvitas 

PsA/Spondyloarthritis Registry 

Robert Low 

Assessment of Pain Outcomes in a Phase 2 Trial 

of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, 

Deucravacitinib, in Patients with Active PsA 

Philip J. Mease 

Assessment of Direct and Indirect Impact on 

Pain and Fatigue Outcomes in a Phase 2 Clinical 

Trial of Deucravacitinib, a Selective, Allosteric 

Tyrosine Kinase 2 Inhibitor, in Patients with 

Active PsA: A Mediation Analysis 


H 

H 

09:00– 

11:00 

0511 

0524 

0527 

14:00– 

15:30 

0739 

0775 

0776 

0779 

0780 

16:00– 

17:00 

12S155 


ARTHRITIS – TREATMENT: AXSPA POSTER I 

Long-term Safety and Tolerability of Bimekizumab 

in Patients with Axial Spondyloarthritis and Psoriatic 

Arthritis: Results from Pooled Phase 2b/3 Studies 


Efficacy of Certolizumab Pegol in Preventing Anterior 

Uveitis Flares Compared with Standard Non-Biologic 

Treatment: A Matched Control Study in High-Risk 

Patients with Axial Spondyloarthritis 

Nigil Haroon 

Bimekizumab Treatment Impact on Pain and 

Fatigue in Patients with Active Psoriatic Arthritis 

Who Were Biologic DMARD Naïve or Had Inadequate 

Response or Intolerance to TNF-α Inhibitors: 1-Year 

Results from Two Phase 3 Studies 

M. Elaine Husni 


ARTHRITIS – TREATMENT I: PSA 

Major Adverse Cardiovascular Event and Venous 

Thromboembolism Risk Comparing Advanced Therapies 

Among Individuals with Axial Spondylarthritis and 

Psoriatic Arthritis 

Sali Merjanah 

Effectiveness of Dose Reduction and Withdrawal Strategies of 

TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: 

Long Term Extension of the DRESS-PS Study 

Amy Peeters 

Efficacy and Safety of Intravenous Secukinumab 

for the Treatment of Active Psoriatic Arthritis: 

16- and 52-Week Results from a Randomized, 

Double-Blind, Phase 3 Study 

Alan Kivitz 

Influence of Sex on the Persistence of Different Classes 

of Targeted Therapies for Psoriatic Arthritis: A Cohort Study 

of 14,778 Patients from the French Health Insurance 

Database (SNDS) 

Laura Pina Vegas 

Assessing Differential Effects of DMARDs on Psoriasis 

Area and Severity Index and Patient Global Assessment 

in Subgroups of Patients with Active PsA Treated over 

52-weeks with Secukinumab in a Non-Interventional Trial 

(AQUILA) Using a Multistage Clustering Approach 

Michaela Koehm 

EPIDEMIOLOGY, HEALTH POLICY AND OUTCOMES 

Chairs: Kristi Kuhn, Michael Weisman 

FDA Update on Safety Issues in the Treatment of 

Rheumatic Diseases 

Eric Gapud, Nadia Habal, Anil Rajpal 

H 

H 

H

KEY: 

H 





Monday, 13 November 2023 

09:00– 

11:00 

1041 

09:00– 

11:00 

1132 

09:00– 

11:00 

1210 

09:00– 

11:00 

1390 

1394 

09:00– 

11:00 

1412 

1413 

1414 

IMAGING OF RHEUMATIC DISEASES POSTER I 

Efficacy of Apremilast on Peripheral and Axial Inflammation 

in Patients with Psoriatic Arthritis Based on Whole-Body 

Magnetic Resonance Imaging 

Mikkel Østergaard 

MISCELLANEOUS RHEUMATIC & 

INFLAMMATORY DISEASES POSTER II 

Preclinical Profiles of FZ007-119, a Highly Potent and 

Selective Tyk2 Inhibitor, for the Treatment of Immune 

Mediated Inflammatory Disease 

Shiqun Zhang 

PATIENT OUTCOMES, PREFERENCES, & 

ATTITUDES POSTER II 

Assessing Patient-Reported Drug Efficacy and Adherence 

Among IL-23 Inhibitors for Psoriasis and Psoriatic Arthritis 

Fahad Ahmed 



& OUTCOMES POSTER II: IMAGING & AS 

Prediction of Low Disease Activity in Patients 

with Ankylosing Spondylitis Treated with 

Secukinumab in Real World – Data from a 

German Observational Study 

Uta Kiltz 

Comorbidities, Not Long-Term Use of Nonsteroidal 

Anti-Inflammatory Drugs, May Be Associated with Chronic 

Kidney Disease in Patients with Ankylosing Spondylitis: 

A Nationwide Population-Based Study 

Bon San Koo 


ARTHRITIS – TREATMENT POSTER II: SPA 

Improvements in Patient-Reported Outcomes H 

Through 6 Months of Guselkumab Treatment in 

Patients with Active Psoriatic Arthritis: Real World Data 

from the CorEvitas Psoriatic Arthritis/Spondyloarthritis 

(PsA/SpA) Registry 


Effect of Apremilast Treatment on the Domains of 

MDA-Joints in Patients with Early Oligoarticular Psoriatic 

Arthritis: 16-Week Results from FOREMOST 


Effects of Apremilast on Changes in Cardiometabolic 

Parameters by Diabetes and Obesity Status in Patients 

with Psoriatic Arthritis 


H 

1415 

1417 

1418 

1419 

1420 

1421 

1422 

1423 

1424 

1425 

1426 

Bimekizumab Treatment Impact on Work Productivity 

in Biologic DMARD-Naïve and TNFi-IR Patients with 

Active Psoriatic Arthritis: Results up to 1 Year from Two 

Phase 3 Studies 


Do Long-term Patient-reported Outcomes 

H 

Improve Similarly in Psoriatic Arthritis and Axial 

Spondyloarthritis Patients Treated with Secukinumab? 

Results from the EuroSpA Collaboration 

Marion Pons 

Efficacy of the Oral, Selective, Allosteric Tyrosine H 

Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in 

Patients with Active PsA: Results from a Phase 2 Trial 

Alice B. Gottlieb 

Impact of Psoriatic Arthritis Manifestations on 

Perception of Pain Improvement: Pooled Analysis 

of Two Phase 3, Randomized, DoubleBlind, 

Placebo-Controlled Studies with Guselkumab 

Peter Nash 

Changes in Serum Cytokines and Collagen Proteins 

Correlate with Durability of Guselkumab Efficacy and 

Continued Disease Improvement Through 2 Years in 

Patients with Active Psoriatic Arthritis 

Stefan Siebert 

Domains Impacting Minimal Disease Activity 

Non-Achievement in Patients with Psoriatic Arthritis 

and Inadequate Response to TNF Inhibitors Receiving 

Guselkumab (COSMOS) 

Laura Coates 

Long-Term Safety of Risankizumab in Patients 

with Psoriatic Disease: Integrated Analysis of 

Psoriasis and Psoriatic Arthritis Clinical Trial Data 

Laura Coates 

Impact of Upadacitinib on Enthesitis and Dactylitis 

by Location in Patients with Psoriatic Arthritis and 

an Inadequate Response to Biologic DMARDs from 

the SELECT-PsA 2 Trial 

Laura Coates 

Early Fatigue Improvement with Guselkumab Associates 

with Longer Term Disease Control in Patients with Active 

Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc 

Analyses of a Sub-Population of a Phase 3, Randomized, 

Controlled Trial of Guselkumab in Biologic-Naïve Patients 

Dafna Gladman 

Efficacy and Safety of Tofacitinib in an 

Open-Label, Long-Term Extension Study in 

Patients with Psoriatic Arthritis Who Received 

Adalimumab or Tofacitinib in a Phase 3 Randomized 

Controlled Study: A Post Hoc Analysis 

Dafna Gladman 

Distinct Treatment Response Trajectories in Patients with 

Psoriatic Arthritis Receiving Tofacitinib 

Dafna Gladman 

H 

H 

H 

H

KEY: 

H 





1427 

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis 

Stratified by Involvement of Weight-bearing Joint Regions: 

A Post Hoc Subgroup Analysis of the Phase 3, Randomized, 

SELECT-PsA 1 and SELECT-PsA 2 Trials 

Kristi Mizelle 

1439 

Better Drug Retention on anti-IL17A Compared to 

Anti-TNF Therapy Despite Its Inferior Effect on Composite 

Joint Indexes and Quality of Life in Patients with 

PsA–analysis from the Czech Biologics Registry ATTRA 

Jakub Zavada 

1428 

1429 

Guselkumab Provides Clinically Meaningful 

Improvents in Patient Reported Outcomes in 

Patients with Active Psoriatic Arthritis Who Are 

Inadequate Responders to Tumour Necrosis Factor 

Inhibitors: Results Through One Year of a Phase 3b, 

Randomized, Controlled Study (COSMOS) 

Laure Gossec 

Longitudinal Evaluation of the Novel Psoriatic Arthritis 

5-Thermometer Scale (PsA-5Ts) Domains During Treatment 

with Guselkumab: Pooled Analysis of Three Phase 3, 

Randomized, Double-blind, Placebo-Controlled Studies 

Carlo Selmi 

H 

1440 

16:00– 

17:30 

1687 

Removal of Methotrexate in Patients with Active Psoriatic 

Arthritis with Newly Induced Ustekinumab Treatment Leads 

to a Delayed Response in DAPSA and DAS28 Within the 

First 16 Weeks 

Michaela Koehm 


ARTHRITIS – TREATMENT II: PSA 

Sex of the Patient Affects Response to Advanced 

Therapies in Psoriatic Arthritis: Meta-analysis of Data from 

Randomized Controlled Trials 

Lihi Eder 

1431 

Izokibep, a Unique IL-17A Inhibitor, Improves 

Patient-Reported Outcomes in Patients with 

Active Psoriatic Arthritis up to Week 46 – Phase 2 

RCT Results 

Peter C. Taylor 

H 

1688 

Izokibep Demonstrates Major Disease Control 

on ACR70, PASI100 and Enthesitis Resolution 

in Patients with Active Psoriatic Arthritis Treated 

Through 46 Weeks 


H 

1433 

1434 

1435 

Bimekizumab Impact on Core Group for Research H 

and Assessment of Psoriasis and Psoriatic Arthritis 

(GRAPPA) Domains for Patients with Psoriatic Arthritis: 

52-Week Results from Four Phase 3 Studies 

Joseph Merola 

Long-Term Efficacy and Safety of Risankizumab 

for Active Psoriatic Arthritis: 148-Week Results 

from the KEEPsAKE 2 Trial 

Andrew Östör 

Long-Term Efficacy and Safety of Risankizumab H 

for CsDMARD-IR Patients with Active Psoriatic 

Arthritis: 148-Week Results from the KEEPsAKE 1 Trial 

Lars Erik 

H 

1690 

1691 

1692 

Apremilast Reduces Inflammation as Measured by MRI of 

the Hand in Patients with Psoriatic Arthritis: Primary Results 

from the Phase 4 MOSAIC Study 

Mikkel Østergaard 

16-Week Results from FOREMOST, a Placebo- 

Controlled Study Involving Oligoarticular Psoriatic 

Arthritis Treated with Apremilast 


Insights on the Use of JAK-inhibitors in Patients with 

Psoriatic Arthritis in an International Collaboration of 

Registers (the “JAK-pot” Study) 

Romain Aymon 

H 

1436 

Secukinumab Demonstrates a Consistent Safety 

Profile in Patients with Psoriasis, Psoriatic 

Arthritis and Axial Spondyloarthritis: Updated 

Pooled Safety Analysis from Clinical Trials 

Atul Deodhar 

H 

1437 

Bimekizumab Maintained Efficacy Responses 

Through 52 Weeks in Biologic Disease-Modifying 

Antirheumatic Drug-Naïve Patients with Psoriatic 

Arthritis Who Were Responders at Week 16: 

Results from a Phase 3, Active-Reference Study 

William R. Tillett 

H 

1438 

Efficacy of Guselkumab in Early-Onset and 

Late-Onset Psoriatic Arthritis: Post Hoc Pooled 

Analyses of Two Phase 3 Randomized Controlled 

Trials in Patients with Active PsA 

Enrique Soriano 

H

KEY: 

H 





Tuesday, 14 November 2023 

09:00– 

11:00 

1891 

09:00– 

11:00 

0265 

1920 

09:00– 

11:00 

2145 

2146 

09:00– 

11:00 

2199 

09:00– 

11:00 

2227 

2228 

2229 

IMAGING OF RHEUMATIC DISEASES POSTER II 

Effect of Apremilast on Disease Interception in Patients with 

Psoriasis at Increased Risk of Developing PsA – Results of 

the Prospective Interventional Epos Trial 

David Simon 

MISCELLANEOUS RHEUMATIC & 

INFLAMMATORY DISEASES POSTER III 

Differential and Combinatorial Mechanism of Action of 

Golimumab and Guselkumab in Ulcerative Colitis Induction 

Therapy: IL-23 Blockade Drives Restoration of Normal 

Epithelium and Mucosal Healing 

Dennis McGonagle 

A Phase Ib/II Randomized, Double-blind, Placebo-controlled 

Study of Novel anti-IL-17A Monoclonal Antibody JS005 in 

Patients with Moderate to Severe Psoriasis 

Zhanglei Mu 

RA – TREATMENTS POSTER III 

Patterns of Use, Effectiveness, Persistence and Cardiovascular 

Risk in Patients with Rheumatic Diseases Treated with 

Upadacitinib in a Real-world Setting. UPAREAL Study 

Alicia Garcia Dorta 

After JAK Inhibitor Failure, “Switching” or “Cycling”? 

Pablo Francisco Muñoz Martínez 



& OUTCOMES POSTER III: SPA 

Four-year Secukinumab Treatment Outcomes 

in Axial Spondyloarthritis and Psoriatic Arthritis 

Patients Treated in Routine Care: Results from 

the EuroSpA Collaboration 

Marion Pons 


ARTHRITIS – TREATMENT: SPA POSTER III 

The Impact of Smoking Status on One Year Secukinumab 

Retention Rate in 1,684 Patients with PsA: Real-World 

Results from the EuroSpA Collaboration 

Zohra Faizy Ahmadzay 

Early Improvement in 3 Visual Analogue Scale (3VAS)/4VAS 

Predicts Reduced Rates of Radiographic Change in 

Bio-naive Active Psoriatic Arthritis Patients Receiving 

Guselkumab Treatment 

William R. Tillett/Laura Coates 

Individual Entheseal Points Have Differential Frequency 

of Involvement and Impact on Patient Reported 

Outcomes in Patients with Active Psoriatic Arthritis: 

Pooled Analysis of Two Phase 3, Randomized, 

Double-Blind, Placebo-Controlled Studies 

Laura Coates 

H 

2230 

2231 

2232 

2233 

2236 

2237 

2238 

2239 

2240 

2241 

2242 

2243 

2244 

Bimekizumab Treatment in Patients with Active 

PsA and Prior Inadequate Response to TNF Inhibitors: 

Sustained Efficacy and Safety Results from a Phase 3 

Study and Its Open-Label Extension up to 1 Year 

Laura Coates 

Ixekizumab Significantly Improves Nail Disease and 

Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis 


Guselkumab, an IL-23p19 Subunit–specific Monoclonal 

Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently 

Neutralize IL-23 Produced from the Cells, and Mediate 

Internalization of IL-23 


Neutrophil Levels Associate with Early Improvement in Spinal 

Pain and Week 24 Multi-Domain Disease Control During 

Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc 

Pooled Analyses of Two Phase 3 Randomized Controlled Trials 

Thomas Macleod 

Guselkumab Provides Rapid Clinically Meaningful 

Improvements in Clinical and Patient Reported Outcomes 

and Sustained Disease Control of Psoriatic Arthritis 

Jeffrey R. Curtis 

Upadacitinib in Refractory Psoriatic Arthritis. 

Multicenter Study of 134 Patients in Clinical Practice 

Eva Galindez-Agirregoikoa 

Longitudinal Effect of Guselkumab on Biomarkers 

of Inflammation and Cardiovascular Risk in Bionaive 

Patients with Active Psoriatic Arthritis and High Systemic 

Inflammatory Burden: Post-hoc Analysis of a Phase 3, 

Randomized, Double-blind, Placebo-Controlled Study 

Arthur Kavanaugh 

Achievement of Disease Control in PsA Patients Treated 

with Upadacitinib at Week 152: Post Hoc Analysis of the 

Long-term Extensions of Two Phase 3 Trials 

Arthur Kavanaugh 

Persistence to Therapy Among Patients with Psoriatic Arthritis 

Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi) 

Aisha Vadhariya/Sarah Ross 

Guselkumab Efficacy in Active Psoriatic Arthritis Patients with 

or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, 

Randomized, Doubleblind, Placebo-Controlled Studies 

Renaud Felten 

Irrespective of the Number of Erosions at Baseline, 

Patients with Psoriatic Arthritis Treated with Ixekizumab 

Show Improved Clinical Outcomes 

M. Elaine Husni 

Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis 

Responsiveness: Week 52 Results of an Exploratory Analysis 

from a Phase 3b Study in Patients with Psoriatic Arthritis 

Maria Antonietta D’Agostino 

Switching Between Biologics and Targeted Synthetic 

Therapies Due to Inefficacy in Psoriatic Arthritis 

Dalifer Freites Núñez 

H

KEY: 

H 





2245 

2246 

2249 

2250 

2251 

2252 

2253 

2254 

16:00– 

17:30 

2505 

Drug Survival of Risankizumab vs Other Biologics After 

13 Months of Treatment Among Patients with PsA in the 

Multicountry Postmarketing Observational VALUE Study 

Lars Erik 

Real-World Switching and Discontinuation Patterns for 

Biologic Disease-Modifying Antirheumatic Drugs in Patients 

with Active Psoriatic Arthritis in Japan 

Lars Erik 

Bimekizumab-Treated Patients with Active PsA Showed 

Sustained Improvement in Disease Symptoms Assessed 

by the PsA Impact of Disease (PsAID)-12 Questionnaire: 

1-Year Results Reported from Two Phase 3 Studies 

Dafna Gladman 

Bimekizumab Impact on Health-Related Quality of Life and 

Physical Function in Patients with Active Psoriatic Arthritis 

Who Were Biologic DMARD Naïve or Had Inadequate 

Response or Intolerance to TNF-α Inhibitors: 1-Year Results 

from Two Phase 3, Randomized Studies 

Dafna Gladman 

Direct and Indirect Effects of Upadacitinib 

or Adalimumab on Pain in Psoriatic Arthritis: 

Results from a Randomized Phase 3 Study 

Peter C. Taylor 

Bimekizumab Maintained Efficacy Responses Through 

52 Weeks in Patients with Psoriatic Arthritis and 

Inadequate Response or Intolerance to TNF-α Inhibitors 

Who Were Responders at Week 16: Results from a 

Phase 3, Randomized Study 

William R. Tillett 

Deucravacitinib, an Oral, Allosteric, Selective Tyrosine 

Kinase 2 Inhibitor, in Patients with Plaque Psoriasis Who 

Screened Positive for Psoriatic Arthritis in POETYK PSO-1 

and POETYK PSO-2: Effect on Joint Pain and Peripheral 

Joint Disease vs Placebo and Apremilast 

Joseph Merola 

The Effects of Interleukin 17 Inhibitors on Major Adverse 

Cardiovascular Events in Patients Naïve to Biologic Agents 

with Psoriasis or Psoriatic Arthritis: A Systematic Review 

and Meta-Analysis of Randomized Controlled Trials 

Ruoning Ni 

CYTOKINES & CELL TRAFFICKING 

Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for 

the Treatment of Inflammatory Disorders 

Kate Byth 

H 

Wednesday, 15 November 2023 

09:00– 

10:30 

2566 

9:15– 

10:15 

15W112 

EPIDEMIOLOGY & PUBLIC HEALTH III 

Comparisons of the Risk of Serious Infections Associated 

with the Different Classes of Targeted Therapies Used in 

Psoriatic Arthritis Patients: A Nationwide Cohort Study from 

the French Health Insurance Database 

Léa Bastard 

SPONDYLOARTHRITIS (SPA) INCLUDING 

PSORIATIC ARTHRITIS (PSA) 

Chairs: M. Elaine Husni 

Getting Skin and Joint in the Game: Key Players in the 

Psoriatic Arthritis Microenvironment 

Ursula Fearon, Christopher Ritchlin, Jose Scher 

Satellite Symposia 

SUNDAY, 12 NOVEMBER 2023 

11:30– 

12:15 

18:00– 

20:00 

18:00– 

20:00 

18:00– 

20:00 

Treating Patients with PsA and AS Today & Tomorrow 

Sponsor: Eli Lilly Chair: Ara Dikranian 

Novartis’ Commitment in Rheumatology 

Sponsor: Novartis Chairs: Adam Winseck, Antton Egana, 

Kelly Montalto 

The IL-17 Story: All in the Family 

Sponsor: UCB, Inc Chair: Dirk Elewaut 

Reaching Beneath the Surface: Exploring treatment that 

addresses multiple domains with a well-documented safety 

profile for adult patients with active PsA 

Sponsor: AbbVie Chair: Alan Epstein 

MONDAY, 13 NOVEMBER 2023 

18:00– 

20:00 

Navigating the Complexities of Individualized Treatment in 

Psoriatic Arthritis and Axial Spondyloarthritis 

Sponsor: Eli Lilly Chairs: Arthur Kavanaugh, 

Catherine Bakewell, 

Atul Deodhar, Alexis Ogdie 

TUESDAY, 14 NOVEMBER 2023 

18:00– 

20:00 

Raising the Bar: Optimizing Outcomes with IL-23/IL-17 

Inhibitors in Spondyloarthritis 

Sponsor: UCB Chairs: Lianne S. Gensler, 

Ana-Maria Orbai, 

Victoria Navarro-Compán 

Register for FREE content at 

www.cytokinesignalling.com 

Follow us at: 

Cytokine Signalling Forum 

SPONSORSHIP AND UNRESTRICTED 

EDUCATIONAL GRANTS FROM 

DEVELOPED UNDER 

THE AUSPICES OF THE

CSF ACR 2023 PsA Highlights

Create successful ePaper yourself

Delete template?

Save as template?